In pre­lim­i­nary read­out, GSK notch­es win for meningo­coc­cal vac­cine

GSK said its next-gen­er­a­tion meningo­coc­cal vac­cine is just as good as cur­rent­ly avail­able vac­cines Bexsero and Men­veo in peo­ple be­tween the ages of 10 and 25 years old.

The new vac­cine com­bines the strains from Bexsero and Men­veo, which aim to pro­vide pro­tec­tion against five vari­ants of the dis­ease known as A, B, C, W and Y.

The com­bined vac­cine, MenABCWY, is cur­rent­ly be­ing test­ed in a Phase III non­in­fe­ri­or­i­ty tri­al, com­par­ing it to the two al­ready avail­able vac­cines. The com­bined vac­cine is ad­min­is­tered as two dos­es giv­en six months apart to peo­ple be­tween the ages of 10 and 25 years old, com­pared to the com­bi­na­tion of one dose of Men­veo and two dos­es of Bexsero. Ac­cord­ing to GSK, the strains in the com­bined vac­cine ac­count for 95% of those cir­cu­lat­ing in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.